Therachon
Therachon is a privately held, clinical-stage biotechnology company based in Basel, Switzerland, developing therapeutics for rare, genetic diseases. It operates a multi-asset rare-disease pipeline built through venture funding and the 2018 acquisition of GLyPharma Therapeutic.
- Company typePublic
- Founded1849
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Therachon does
Therachon is a privately held, clinical-stage biotechnology company founded in 2014 and headquartered in Basel, Switzerland. The company is focused on developing medicines for rare, genetic diseases, operating in a therapeutic area where unmet medical need is high and regulatory pathways such as orphan-drug designation can be commercially attractive. Based on the input, the company is described as 'global' in scope despite its lean headcount of 1-10 employees, consistent with a development-stage biotech that intends to run clinical programs across multiple geographies.
The company's pipeline and technology base are anchored in biological assets targeting rare genetic conditions, with its lead activity focused on a single-asset rare-disease program around the time of the 2018 funding events. In October 2018, Therachon expanded its pipeline via the acquisition of GLyPharma Therapeutic, which added a GLP-2 analog program (commonly associated with short bowel syndrome) to the portfolio, signaling a deliberate move from a single-asset to a multi-asset rare-disease platform. The input does not disclose specific underlying modalities (e.g., recombinant protein, antibody, gene therapy) in granular detail, so the technology description is limited to the broad characterization of a rare-disease therapeutics platform.
Therachon's business model is consistent with a venture-backed, pre-commercial biotech: the company has raised approximately $100 million across three funding rounds between 2015 and 2018, with investors including OrbiMed, Versant Ventures, Inserm Transfert Initiative, New Enterprise Associates, Bpifrance, Cowen Healthcare Investments, Tekla Capital Management, Novo Holdings, and Pfizer Venture Investments. There are no disclosed products, customers, pricing models, or commercial revenue streams in the input. Future monetization, if executed as planned, would most likely take the form of out-licensing, partnership agreements, or a strategic acquisition, rather than direct sales given the absence of commercial infrastructure in the provided data. Leadership consists of a Chairman & Managing Director (Tom Woiwode) and a COO (Richard Porter).
Therachon firmographics
Firmographics- Name
- Therachon
- Legal name
- Pfizer Inc.
- Website
- https://therachon.com
- Company type
- Public
- Founded year
- 1849
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Therachon is a privately held, clinical-stage biotechnology company based in Basel, Switzerland, developing therapeutics for rare, genetic diseases. It operates a multi-asset rare-disease pipeline built through venture funding and the 2018 acquisition of GLyPharma Therapeutic.
- Ownership category
- akta.pro rank
Therachon industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industries
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
Keywords
Where Therachon is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Therachon business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Therachon product offering
Product offeringCore offering
Therachon is a clinical-stage biotechnology company developing biopharmaceutical therapies for rare, genetic diseases, with a focus on conditions such as achondroplasia and other skeletal dysplasias. The company builds a pipeline of protein-based and biologic drug candidates targeting well-characterized genetic pathways, advancing them through preclinical and clinical development toward potential licensing, partnership, or commercialization.
Differentiator
Problem solved
Functional benefit
Brands
- Pfizer CentreOne: A partner for business and research collaborations, offering contract manufacturing and pharmaceutical development services.
- PfizerForAll
- PfizerPro
- Pfizer RxPathways
Companies that use Therachon
Customer profileIdeal customer profiles1 record
Therachon technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Therachon partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
Therachon competitors and assessment
Company assessmentDirect peers
- BioMarin Pharmaceutical: BioMarin is a global rare-disease biotech with a leading achondroplasia program (vosoritide) directly competing with Therachon's lead rare skeletal dysplasia focus. Both target the same monogenic growth disorder via differentiated mechanisms.
- Ascendis Pharma: Ascendis Pharma develops therapeutics for rare endocrine and growth disorders, including FGFR3-pathway-adjacent conditions. Direct overlap with Therachon's rare pediatric growth disorder focus and orphan-drug strategy.
- Ultragenyx Pharmaceutical: Ultragenyx is a clinical-to-commercial rare and ultra-rare genetic disease biotech with a multi-asset pipeline addressing monogenic conditions. Therachon's rare-genetic disease focus and similar orphan-drug commercial model make it a closely comparable specialty biotech.
Broad incumbents
- Alexion (AstraZeneca Rare Disease): Alexion is the established global leader in rare-disease therapeutics, now part of AstraZeneca. While broader in scope, its orphan-drug commercial infrastructure, payer relationships, and rare-disease M&A appetite make it a key benchmark and potential acquirer for Therachon.
- Sanofi Genzyme (Rare Disease): Sanofi's Genzyme unit is one of the largest rare-disease commercial organizations globally. Relevant both as a competing developer of rare genetic therapies and as a potential strategic partner/acquirer for Therachon.
- Takeda Pharmaceutical (Rare Diseases): Takeda has built a meaningful rare-disease franchise (post-Shire) and pursues licensing and M&A in rare genetic disorders. Comparable as a potential strategic acquirer/partner for Therachon's rare-disease assets.
- Pfizer: Pfizer is one of the world's largest biopharmaceutical companies and participated in Therachon's 2018 round through Pfizer Venture Investments. Highly comparable as both a potential strategic acquirer of rare-disease biotechs and a benchmark for orphan-drug pipeline economics.
Emerging players
- Regenxbio: Regenxbio develops AAV gene therapies for rare monogenic diseases including metabolic and pediatric genetic conditions. Comparable to Therachon on target indication class (rare monogenic disorders) and orphan-drug commercial model, though distinct on modality.
- QED Therapeutics: QED Therapeutics (a BridgeBio subsidiary) develops infigratinib and other FGFR-pathway inhibitors, including for rare skeletal disorders. Strong mechanistic and indication overlap with Therachon's FGFR3-targeted rare disease programs.
- Enzyvant Therapeutics: Enzyvant is a clinical-stage rare-disease biotech developing regenerative therapies for single, ultra-rare indications. Compares to Therachon in company stage, funding profile, and orphan-drug regulatory pathway.
Market position
Weaknesses4 records
Competitive moat3 records
Key risks1 record
Key highlights1 record
Customer concentration
Therachon social profiles
Digital presenceTherachon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Therachon leadership team
Management profileNumber of profiles
Profiles2 records
Therachon funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Therachon M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Therachon
What does Therachon do?
Therachon is a clinical-stage biotechnology company developing biopharmaceutical therapies for rare, genetic diseases, with a focus on conditions such as achondroplasia and other skeletal dysplasias. The company builds a pipeline of protein-based and biologic drug candidates targeting well-characterized genetic pathways, advancing them through preclinical and clinical development toward potential licensing, partnership, or commercialization.
Is Therachon a public or private company?
Therachon is a public company. It is classified as venture growth investor backed and is currently operating.
When was Therachon founded?
Therachon was founded in 1849. It employs 1 to 10 people.
Where is Therachon based?
Therachon is headquartered in Basel, Switzerland, in the Europe region.
Who are Therachon's main competitors?
Direct peers on record are BioMarin Pharmaceutical, Ascendis Pharma and Ultragenyx Pharmaceutical. Broad incumbents are Alexion (AstraZeneca Rare Disease), Sanofi Genzyme (Rare Disease), Takeda Pharmaceutical (Rare Diseases) and Pfizer. Emerging players are Regenxbio, QED Therapeutics and Enzyvant Therapeutics.
Does Therachon have an API?
No public API is recorded for Therachon.
What industry is Therachon in?
Therachon's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.